Feb 8, 2008 by Brian LawlerAlpharma Doing Its Best Endo ImitationAlpharma sells one of its business units.
Feb 7, 2008 by Brian LawlerBiogen Rests RumorsThe pharmaceutical announces its year-end financial results.
Feb 6, 2008 by Brian LawlerCVT Finds a Partner in a Clogged MarketCV Therapeutics out-licenses one of its technologies.
Feb 6, 2008 by Brian LawlerPDL BioPharma Regroups, Piece by PieceThe company still brings in plenty of money, despite selling off assets.
Feb 6, 2008 by Brian LawlerNeurocrine on the Upswing?Neurocrine updates investors on the status of its top drugs.
Feb 5, 2008 by Brian LawlerDrugmakers and the ElectionWill a new president bring big changes for these companies?
Feb 4, 2008 by Brian LawlerBest International Stock: Novo NordiskNovo Nordisk is one of the best stocks in the world.
Feb 4, 2008 by Brian LawlerGenzyme Tells It Like It IsGenzyme shows some sparkle at investors' conference.
Feb 4, 2008 by Brian LawlerDisenchanted With ChantixThe FDA issues a health advisory for a top Pfizer drug.
Feb 1, 2008 by Brian LawlerAstraZeneca's Trying to Get HealthierThe big pharma tries to get back on track.
Feb 1, 2008 by Brian LawlerCredit Crisis Bites Big PharmaBristol-Myers Squibb takes a $275 million writedown in its investment portfolio for the quarter.
Feb 1, 2008 by Brian LawlerLooking at InterMune's Lead DrugInterMune updates investors on its progress at the Wachovia Healthcare Conference.
Feb 1, 2008 by Brian LawlerAlexion Looks for a Bigger NicheSales of its lead drug should expand in 2008.
Jan 31, 2008 by Brian LawlerWho Let the Docs Out?A leaked, confidential journal article could get Glaxo in hot water.
Jan 31, 2008 by Brian LawlerA Zettlement for Zyprexa?Eli Lilly may be close to resolving a government lawsuit over improper marketing.
Jan 31, 2008 by Brian LawlerPrioritizing MillenniumThe FDA grants a speedy review for Millennium's lead drug.
Jan 31, 2008 by Brian LawlerWhen Nutraceuticals AttackNeurochem gets another step closer to a bad idea.
